puumala
viru
puuv
hantaviru
carri
chronic
infect
bank
vole
caus
agent
estim
case
yearli
viral
hemorrhag
fever
europ
vapalahti
et
al
vaheri
et
al
hantavirus
rodentborn
neg
strand
rna
virus
belong
bunyavirida
famili
may
caus
two
type
diseas
human
goeijenbi
et
al
europ
asia
hantaviru
infect
caus
hemorrhag
fever
renal
syndrom
hfr
character
renal
failur
bleed
complic
north
south
america
hantaviru
infect
caus
hantaviru
cardiopulmonari
syndrom
hcp
patient
present
sever
acut
respiratori
distress
sargian
et
al
chang
ecolog
factor
determin
fluctuat
hantaviru
epidemiolog
result
sudden
increas
incid
instanc
increas
food
avail
prolong
viru
surviv
decreas
biodivers
reusken
heyman
recent
epidemiolog
studi
report
overal
incid
increas
puuv
infect
europ
heyman
vaheri
although
puuv
infect
low
case
fatal
rate
literatur
viru
often
describ
least
virul
pathogen
virus
within
hantaviru
genu
puuv
infect
caus
sever
diseas
healthi
adult
may
requir
long
recoveri
period
last
year
schmaljohn
hjell
furthermor
sever
report
describ
case
sever
hemorrhag
complic
like
pituitari
gland
hemorrhag
hematemesi
gastrointestin
bleed
eckerl
et
al
antonen
et
al
contrast
bleed
complic
recent
studi
sweden
report
increas
risk
acut
myocardi
infarct
shortli
puuv
infect
connollyandersen
et
al
given
high
incid
northern
europ
acut
myocardi
infarct
complic
puuv
infect
could
major
impact
endem
area
light
bleed
thrombot
event
might
complic
puuv
infect
hypothes
endotheli
cell
also
target
cell
hantavirus
major
regul
coagul
inflamm
play
central
role
pathogenesi
diseas
zhou
et
al
hantaviru
infect
drastic
alter
coagul
system
observ
lain
et
al
clinic
studi
focus
primari
secondari
hemostasi
hantaviru
diseas
show
thrombocytopenia
hfr
hcp
decreas
plasma
activ
coagul
factor
ii
v
viii
ix
x
acut
hfr
patient
prolong
prothrombin
activ
partial
thromboplastin
time
increas
thrombin
gener
ddimer
level
decreas
activ
acut
puuv
patient
lee
mackow
gavrilovskaya
lain
et
al
mustonen
et
al
abil
infect
endotheli
cell
hantavirus
demonstr
vitro
vivo
yanagihara
silverman
pensiero
et
al
toro
et
al
although
infect
lead
cytopath
chang
sever
studi
observ
endotheli
cell
dysfunct
hantaviru
infect
yanagihara
silverman
pensiero
et
al
mackow
gavrilovskaya
rang
increas
clinic
marker
stress
endothelium
vivo
vwf
circul
endotheli
cell
han
et
al
krautkram
et
al
increas
permeabl
decreas
huvec
integrin
ligand
migrat
vitro
gavrilovskaya
et
al
geimonen
et
al
taylor
et
al
integrin
experiment
proven
receptor
hantaviru
infect
abundantli
present
surfac
endotheli
cell
gavrilovskaya
et
al
song
et
al
infect
pathogen
hantavirus
suggest
result
loss
function
integrin
wang
et
al
also
increas
express
cultur
endotheli
cell
platelet
observ
liu
et
al
furthermor
gavrilovskaya
et
al
studi
adher
quiescent
platelet
sin
nombr
hantaan
viru
infect
endotheli
cell
seem
result
viru
bind
integrin
present
platelet
gavrilovskaya
et
al
abnorm
primari
thrombocytopenia
secondari
hemostasi
increas
thrombin
gener
rais
ddimer
level
induc
puuv
infect
patient
mechan
oldworld
hantavirus
caus
hemorrhag
andor
renal
failur
remain
larg
elus
vaheri
et
al
lack
specif
treatment
effect
vaccin
make
understand
pathophysiolog
hantaviru
infect
import
medic
need
especi
recent
discov
associ
puuv
cardiovascular
diseas
connollyandersen
et
al
therefor
use
integr
approach
studi
chang
primari
secondari
hemostasi
use
vitro
endotheli
cell
model
cell
american
type
cultur
collect
usa
grown
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
lonza
netherland
uml
penicillinstreptomycin
solut
hepe
buffer
sodium
bicarbon
gibco
life
scienc
usa
human
umbil
vein
endotheli
cell
huvec
harvest
umbil
vein
kindli
provid
erasmu
mc
birth
center
briefli
umbil
cord
store
steril
ml
pb
supplement
gentamycin
leo
pharmaceut
denmark
vein
rins
pb
contain
uml
heparin
leo
pharmaceut
subsequ
cell
detach
collagenas
solut
sigma
aldrich
usa
cell
suspens
collect
steril
ml
tube
follow
two
time
centrifug
min
g
cell
pellet
resuspend
huvec
medium
human
endothelialsfm
medium
invitrogen
life
scienc
usa
contain
human
serum
lonza
filtrat
fb
lonza
penicilinstreptomycin
uml
ngml
fibroblast
growth
factor
peprotech
usa
ngml
endotheli
cell
growth
factor
peprotech
huvec
cell
suspens
cultur
flask
precoat
fibronectin
roch
netherland
cell
passag
four
one
specif
donor
use
studi
ident
endotheli
cell
confirm
flow
cytometri
use
ulex
europeu
lectin
von
willebrand
factor
vwf
stain
immunoblot
made
use
follow
antibodi
conjug
polyclon
rabbit
anti
vwf
hrp
label
polyclon
goat
antirabbit
igg
polyclon
rabbit
antimous
dako
netherland
fitc
label
monoclon
sigma
aldrich
usa
polyclon
rabbit
perbio
scienc
netherland
polyclon
rabbit
dako
polyclon
rabbit
antipuuv
nucleoprotein
bei
resourc
usa
monoclon
antipuuv
glycoprotein
hy
test
finland
monoclon
integrin
abcam
uk
monoclon
antivitronectin
novu
bio
usa
polyclon
rabbitanti
bio
connect
netherland
polyclon
rabbit
antitissu
factor
tf
bio
connect
human
serum
recov
puuv
case
describ
goeijenbi
et
al
retriev
inform
consent
ethic
board
approv
antibodi
conjug
dilut
dilut
buffer
consist
pb
bovin
serum
albumin
nacl
normal
goat
serum
lung
myod
glareolu
konnevesi
finland
infect
puuv
homogen
dmem
wv
ad
onto
monolay
cell
incub
min
supernat
discard
cell
wash
three
time
incub
fresh
medium
addit
day
viru
stock
passag
four
creat
centrifug
min
g
supernat
creat
cell
free
viru
stock
viru
titer
determin
use
immun
peroxidas
reaction
ipox
calcul
use
karber
formula
infecti
viru
inactiv
use
betapropiolacton
bpl
sigma
aldrich
usa
vv
h
subsequ
bpl
inactiv
h
viru
stock
store
use
experi
conduct
biosafeti
instruct
requir
regard
work
live
puuv
vesicular
stomat
viru
vsv
strain
indiana
propag
also
cell
kindli
provid
dr
bart
haagman
erasmu
mc
human
umbil
vein
endotheli
cell
seed
cell
plate
cell
corn
usa
depend
experi
confluent
monolay
infect
multipl
infect
moi
infecti
inactiv
bplinactiv
viru
normal
medium
control
min
incub
supernat
discard
cell
wash
three
time
rpmi
gibco
life
scienc
fresh
medium
ad
describ
earlier
vwf
plasminogen
activ
inhibitor
quantif
medium
contain
fc
supplement
steril
filter
bovin
serum
albumin
bsa
sigma
aldrich
usa
avoid
addit
fetal
calf
vwf
zoellner
et
al
quantifi
percentag
infect
cell
use
hous
develop
ipox
procedur
huvec
wash
three
time
pb
cell
fix
absolut
methanol
incub
min
fixat
methanol
discard
cell
incub
min
pb
block
endogen
peroxidas
subsequ
cell
wash
three
time
pb
incub
min
polyclon
rabbit
antipuuv
nucleoprotein
antibodi
cell
wash
pb
tween
follow
incub
hrplabel
goat
antirabbit
igg
conjug
color
develop
achiev
addit
aec
substrat
aec
dissolv
dimethylformamid
buffer
acet
buffer
ph
percentag
infect
cell
determin
manual
count
quantif
viral
replic
use
standard
line
hous
gener
puuv
rna
runoff
transcript
describ
westnil
viru
lim
et
al
briefli
rna
runoff
transcript
gener
use
segment
amplifi
panhantaviru
degen
pcr
primer
johansson
et
al
pcr
product
separ
agaros
gel
band
correct
size
collect
dna
gel
extract
use
minelut
gel
extract
kit
protocol
qiagen
usa
dna
fragment
clone
vector
use
ta
clone
kit
life
technolog
one
chemic
compet
escherichia
coli
transform
recombin
vector
qiagen
accord
manufactur
protocol
least
five
coloni
collect
analys
plasmid
dna
purifi
use
minelut
dna
purif
kit
qiagen
plasmid
dna
linear
restrict
digest
noti
neg
strand
rna
psti
posit
strand
rna
runoff
transcript
vitro
transcript
synthes
use
rna
polymeras
neg
strand
rna
polymeras
posit
strand
transcript
kit
life
technolog
follow
dnase
treatment
turbo
dnafreetm
life
technolog
accord
manufactur
manual
amount
rna
stock
determin
use
serial
dilut
copi
number
standard
calcul
use
rna
concentr
sequenc
length
help
onlin
calcul
studi
interact
puuv
platelet
platelet
collect
accord
protocol
describ
gavrilovskaya
et
al
minor
modif
briefli
blood
collect
end
concentr
sodium
citrat
tube
bdplymouth
uk
supplement
prostaglandin
cayman
chemic
usa
block
platelet
activ
plateletrich
plasma
prp
prepar
centrifug
min
subsequ
platelet
pellet
min
g
platelet
wash
twice
resuspend
modifi
hepe
buffer
mm
hepe
mm
nacl
albumin
prostaglandin
ph
count
hematocytomet
platelet
per
ml
incub
infect
huvec
well
plate
puuv
bpl
inactiv
puuv
mock
control
min
incub
monolay
wash
three
time
rpmi
cell
fix
formalin
fixat
formalin
discard
cell
incub
min
pb
three
wash
step
cell
incub
rabbit
polyclon
antihuman
antibodi
follow
step
describ
earlier
ipox
incub
hrplabel
goat
antirabbit
conjug
tmb
ad
well
substrat
reaction
min
reaction
stop
addit
sulphur
acid
optic
densiti
od
measur
nm
use
tecan
elisa
reader
express
od
calcul
subtract
blanc
od
valu
well
incub
without
platelet
detect
antibodi
conjug
rabbit
polyclon
serv
isotyp
control
test
chang
express
relat
direct
bind
puuv
platelet
mechan
shown
hantaan
and
viru
infect
gavrilovskaya
et
al
pull
assay
design
end
first
coat
elisa
plate
puuv
control
viru
vsv
viru
particl
dmem
overnight
follow
platelet
incub
platelet
subsequ
cell
wash
five
time
pb
bound
platelet
quantifi
use
platelet
detect
antibodi
dilut
buffer
follow
conjug
substrat
reaction
express
calcul
subtract
od
measur
well
without
platelet
incub
blanco
correct
direct
aspecif
antibodi
bind
puuv
use
isotyp
control
subsequ
elisa
plate
coat
mous
monoclon
antipuuv
glycoprotein
isotyp
control
antibodi
corona
viru
pb
overnight
follow
incub
puuv
captur
viru
follow
platelet
incub
detect
antibodi
conjug
substrat
reaction
thirdli
confirm
platelet
puuv
bind
elisa
plate
coat
antiplatelet
antibodi
pb
overnight
follow
incub
fresh
isol
platelet
eventu
incub
step
puuv
vsv
follow
hantaviru
detect
antibodi
mous
mab
antipuuvglycoprotein
wash
substrat
reaction
achiev
conjug
addit
tmb
reaction
step
final
step
studi
potenti
block
platelet
bind
puuv
particl
addit
block
step
polyclon
human
anti
puuv
serum
puuv
coat
plate
plate
coat
day
old
viru
free
medium
incub
polyclon
puuv
serum
case
describ
goeijenbi
et
al
puuv
igg
neg
control
human
serum
healthi
volunt
also
follow
platelet
bind
step
detect
earlier
experi
infect
plate
supernat
subsequ
remov
cell
lyse
three
wash
step
use
min
incub
pb
follow
centrifug
min
cellfre
supernat
supernat
cell
lysat
measur
use
antigen
vwf
elisa
kit
accord
manufactur
instruct
zymugen
hyphen
biom
franc
human
umbil
vein
endotheli
cell
well
plate
fix
formalin
incub
rabbit
polyclon
antitf
antibodi
follow
incub
respect
conjug
wash
tmb
ad
substrat
reaction
reaction
stop
min
addit
sulphur
acid
od
nm
valu
measur
tecan
elisa
reader
cell
lysat
prepar
describ
section
von
willebrand
factor
plasminogen
activ
inhibitor
quantif
elisa
plate
coat
mixtur
cell
lysat
pb
night
togeth
standard
curv
recombin
tf
innovin
siemen
healthcar
diagnost
germani
block
well
incub
rabbit
polyclon
antitf
antibodi
follow
incub
respect
conjug
wash
tmb
ad
substrat
reaction
reaction
stop
min
addit
sulphur
acid
od
nm
valu
measur
tecan
elisa
reader
thrombin
gener
plateletpoor
plasma
ppp
measur
directli
huvec
surfac
well
plate
recalcif
pool
citrat
plasma
healthi
donor
ad
monolay
infect
uninfect
cell
summari
cell
wash
three
time
rpmi
freshli
thaw
plasma
ad
monolay
togeth
hepe
buffer
mm
hepe
mm
nacl
albumin
plate
serial
dilut
recombin
tf
innovin
siemen
healthcar
diagnost
germani
absenc
cell
final
hepe
calcium
mm
hepe
mm
nacl
albumin
mm
cacl
ad
plasma
directli
recalcif
od
nm
valu
measur
use
tecan
elisa
reader
kinet
cycl
measur
everi
h
thrombin
gener
time
defin
time
halfmaxim
od
elisa
plate
coat
antivitronectin
antibodi
pb
overnight
incub
supernat
puuv
infect
noninfect
huvec
follow
incub
polyclon
antibodi
subsequ
conjugatesubstr
reaction
pb
incub
use
blanc
control
antibodi
incub
isotyp
control
statist
analys
perform
use
graphpad
prism
window
compar
two
group
made
use
student
ttest
u
depend
distribut
data
comparison
multipl
group
nonparametr
kruskalw
test
use
dunn
multipl
comparison
test
oneway
anova
tukey
multipl
comparison
test
depend
distribut
consid
signific
prevent
puuv
vitro
loss
virul
viru
stock
four
passag
prepar
freshli
isol
huvec
infect
moi
puuv
infect
replic
huvec
summar
figur
noninfect
cell
figur
b
show
red
peroxidas
stain
confirm
specif
puuvstain
h
post
infect
low
moi
infect
onward
figur
small
percentag
cell
infect
strongli
increas
h
figur
result
infect
stain
cell
twentyfour
hour
infect
moi
cell
infect
figur
increas
h
figur
compar
kinet
seen
viral
rna
copi
number
determin
end
viral
rna
number
estim
supernat
figur
cell
lysat
figur
moi
number
viral
rna
increas
significantli
h
kruskalw
p
supernat
well
cell
lysat
confirm
activ
viral
replic
viral
replic
reach
plateau
h
post
infect
furthermor
westernblot
analysi
cell
lysat
puuv
nucleoprotein
confirm
infect
huvec
figur
viral
copi
number
supernat
cell
lysat
huvec
incub
bpl
inactiv
viru
serv
control
nonrepl
viru
consist
rna
copi
number
increas
time
indic
effici
inactiv
viru
bpl
treatment
effici
inactiv
confirm
neg
ipox
stain
huvec
incub
bpl
inactiv
puuv
data
shown
gavrilovskaya
et
al
report
potenti
hantaan
and
viru
bind
quiescent
platelet
via
integrin
sinc
observ
much
import
understand
alter
primari
hemostasi
role
diseas
mechan
hfr
decid
confirm
mechan
puuv
use
differ
approach
first
assess
abil
quiescent
platelet
bind
puuv
infect
huvec
figur
bind
platelet
determin
measur
intens
platelet
glycoprotein
iib
heterodimer
integr
membran
protein
present
platelet
megakaryocyt
express
significantli
higher
huvec
monolay
infect
moi
compar
control
detect
express
differ
platelet
ad
huvec
monolay
suggest
nonspecif
bind
infect
cell
furthermor
differ
od
valu
isotyp
control
use
detect
platelet
base
express
statist
signific
differ
measur
infect
well
well
incub
viru
free
medium
neg
control
h
post
infect
one
way
anova
moi
vs
neg
p
moi
vs
neg
p
h
infect
differ
express
also
signific
moi
infect
well
bpl
inactiv
viru
control
one
way
anova
moi
vs
neg
p
moi
vs
bpl
p
moi
vs
neg
p
taken
togeth
data
indic
platelet
bind
cultur
incub
puuv
huvec
incub
bpl
show
trend
increas
platelet
express
figur
statist
signific
measur
vwf
antigen
cell
free
supernat
vwf
express
surfac
infect
huvec
increas
vwf
product
may
gener
inflammatori
respons
endotheli
cell
could
evok
result
puuv
infect
howev
time
point
platelet
bind
increas
huvec
infect
puuv
show
alter
vwf
activ
determin
elisa
neither
supernat
cell
lysat
data
shown
compar
bpl
neg
control
next
look
whether
platelet
could
bind
directli
puuv
particl
purpos
perform
inhous
develop
platelet
pull
downassay
use
quiescent
platelet
end
sever
experi
conduct
demonstr
specif
bind
figur
show
result
bind
platelet
virusco
elisa
plate
figur
platelet
u
p
adher
plate
directli
coat
puuv
compar
plate
coat
viru
control
vsv
cultur
condit
puuv
subsequ
control
bind
platelet
directli
puuv
particl
due
anoth
factor
present
supernat
made
use
sandwich
elisa
principl
puuv
incub
elisa
plate
well
coat
monoclon
specif
glycoprotein
puuv
control
antibodi
approach
significantli
platelet
bound
well
puuv
captur
compar
well
puuv
captur
u
p
figur
confirm
direct
bind
platelet
puuv
platelet
captur
coat
elisa
plate
incub
viru
follow
detect
puuv
specif
antibodi
control
bind
puuv
detect
antibodi
captur
platelet
control
well
incub
vsv
puuv
detect
significantli
higher
well
incub
puuv
compar
vsv
u
p
figur
experi
collect
suggest
platelet
specif
bind
puuv
final
show
figur
bind
platelet
puuv
particl
could
block
addit
block
step
human
serum
recov
puuv
case
well
coat
puuv
incub
human
serum
proven
puuv
neutral
igg
antibodi
significantli
less
platelet
adher
well
compar
well
incub
puuv
neg
human
control
serum
figur
p
express
well
block
step
compar
neg
control
consist
plate
coat
day
old
vero
viru
free
medium
bind
neutral
igg
antibodi
confirm
incub
goatanti
human
hrp
label
conjug
subsequ
tmb
reaction
test
hypothesi
whether
increas
thrombin
gener
observ
acut
puuv
patient
result
increas
tf
express
endotheli
cell
incub
huvec
infect
puuv
moi
viru
free
day
old
vero
medium
control
polyclon
antitf
antibodi
approach
show
tf
express
significantli
increas
almost
twofold
increas
od
valu
h
post
infect
figur
u
p
cell
infect
puuv
also
show
increas
tf
concentr
cell
lysat
puuv
infect
well
compar
lysat
control
well
figur
mock
bpl
subsequ
want
prove
increas
tf
express
endotheli
cell
surfac
biolog
signific
would
led
increas
thrombin
gener
thrombin
gener
quantifi
directli
infect
endotheli
cell
incub
normal
plasma
cell
initi
coagul
addit
calcium
ion
infect
cell
induc
plasma
clot
faster
due
increas
thrombin
gener
figur
use
calibr
curv
purifi
tf
absenc
endotheli
cell
quantifi
huvec
tf
product
viru
infect
incub
viru
free
medium
control
tf
concentr
show
statist
signific
increas
moi
h
compar
neg
control
huvec
infect
moi
one
way
anova
p
h
post
infect
compar
neg
control
one
way
anova
p
moi
infect
led
higher
level
tf
huvec
surfac
h
post
infect
one
way
anova
p
compar
mock
import
protein
regul
fibrinolysi
show
close
interact
pathogen
hantaviru
receptor
integrin
instanc
vitronectin
stabil
activ
plasma
larg
regul
receptor
mackow
gavrilovskaya
florova
et
al
studi
potenti
chang
regul
fibrinolysi
first
measur
level
cellfre
supernat
supernat
cell
lysat
plate
infect
puuv
control
infect
total
antigen
combin
level
supernat
cell
lysat
significantli
increas
h
post
infect
p
moi
figur
subsequ
test
model
would
bind
vitronectin
sinc
bind
associ
increasedprolong
activ
seiffert
loskutoff
interact
alter
infect
elisa
plate
coat
monoclon
antibodi
vitronectin
incub
supernat
experi
pool
control
moi
infect
well
follow
incub
antibodi
suggest
format
vitronectin
complex
due
increas
od
compar
incub
pb
mean
express
medium
mod
vs
mod
p
supernat
test
separ
puuv
vs
mock
level
vitronectin
complex
increas
puuv
infect
u
p
figur
present
studi
address
platelet
bind
puuv
infect
cell
activ
secondari
hemostasi
endotheli
cell
puuv
infect
lack
valid
access
anim
model
oldworld
hantaviru
infect
remain
depend
ex
vivo
cell
cultur
model
address
question
regard
virul
pathogenesi
vaheri
et
al
take
account
recent
found
associ
puuv
infect
cardiovascular
diseas
connollyandersen
et
al
hemorrhag
complic
may
occur
infect
interact
puuv
coagul
system
especi
warrant
attent
sinc
puuv
tend
rapidli
lose
virul
upon
vitro
cell
passag
use
low
passag
isol
vital
import
nemirov
et
al
therefor
put
lot
emphasi
obtain
low
passag
puuv
isol
optimis
hemostat
assay
right
biosafeti
regul
use
primari
cell
cultur
base
hemostat
chang
seen
sever
clinic
studi
northern
europ
decid
studi
specif
part
coagul
system
vitro
start
studi
effect
puuv
infect
format
platelet
plug
major
event
primari
hemostasi
bind
platelet
puuv
infect
cell
could
explain
thrombocytopenia
acut
puuv
patient
sinc
would
result
wast
loss
platelet
adher
cell
gavrilovskaya
et
al
lain
et
al
especi
make
notic
abil
hantavirus
infect
megakaryocyt
therebi
lead
decreas
product
platelet
addit
loss
platelet
adher
infect
cell
liang
et
al
luttek
et
al
model
seem
puuv
infect
increas
bind
platelet
surfac
huvec
compar
control
cell
figur
assum
increas
express
observ
first
experi
result
increas
number
platelet
huvec
theoret
increas
detect
could
also
due
increas
express
platelet
min
incub
infect
huvec
rather
actual
increas
platelet
number
rule
base
experi
block
extrins
platelet
activ
prostaglandin
treatment
make
platelet
activ
less
like
furthermor
line
studi
perform
pathogen
hantavirus
gavrilovskaya
et
al
test
specif
bind
platelet
puuv
particl
judg
result
platelet
pull
experi
figur
seem
specif
bind
viru
platelet
could
revers
addit
puuv
neutral
antibodi
experi
control
aspecif
bind
antibodi
isotyp
control
experi
factor
present
viru
cultur
medium
day
old
medium
control
bind
platelet
detect
antibodi
directli
puuv
expect
increas
platelet
bind
cooccur
increas
vwf
product
gener
inflammatori
respons
infect
howev
observ
vwf
concentr
chang
puuv
infect
suggest
vwfindepend
mechan
platelet
bind
hfr
result
earlier
studi
show
increas
vwf
concentr
hospit
puuv
patient
lain
et
al
one
keep
mind
overal
plasma
vwf
level
patient
repres
state
total
endotheli
cell
layer
infect
cell
case
model
furthermor
studi
acut
respons
endotheli
cell
first
h
infect
time
point
puuv
patient
gener
consid
hospit
test
increas
vwf
three
condit
control
bpl
puuv
time
huvec
model
could
result
increas
number
cell
sign
vitro
stress
activ
endotheli
cell
sinc
seem
highli
unlik
cell
still
multipli
format
full
monolay
present
time
infect
believ
also
noninfect
cell
show
certain
level
activ
cultur
gavrilovskaya
et
al
first
studi
interact
hantavirus
and
hantaan
platelet
conclud
specif
bind
hantaan
and
viru
particl
particl
integrin
present
endotheli
cell
platelet
interestingli
experi
show
trend
increas
number
platelet
bound
bplinactiv
viru
treat
cultur
suggest
activ
replic
unnecessari
inactiv
viru
bound
cell
surfac
might
also
bind
integrin
present
platelet
howev
hypothesi
mere
base
statist
trend
observ
well
cell
incub
bpl
inactiv
viru
interpret
data
one
take
mind
made
use
moi
bpl
h
bpl
inactiv
viru
replic
therefor
timepoint
bpl
control
like
compar
moi
infect
could
well
case
increas
moi
bpl
infect
compar
result
moi
infect
would
observ
puumala
viru
infect
huvec
directli
increas
express
tf
cell
surfac
cell
lysat
compar
control
result
drastic
activ
secondari
hemostasi
cell
model
puuv
infect
data
direct
clot
assay
cell
monolay
give
interest
insight
potenti
mechan
behind
increas
thrombin
gener
seen
acut
puuv
patient
lain
et
al
clear
procoagul
state
result
increas
express
tf
surfac
puuv
infect
cell
result
enhanc
thrombin
gener
increas
thrombin
gener
decreas
thrombin
time
overal
increas
prothrombin
fragment
antithrombin
protein
c
lain
et
al
observ
acut
puuv
patient
could
well
result
direct
infect
endotheli
cell
concomit
increas
product
tf
whether
increas
tf
gener
defens
respons
viru
actual
benefit
tf
seen
certain
herpesviru
infect
pryzdial
et
al
remain
unknown
howev
excess
tf
product
infect
could
lead
increas
clot
eventu
consumpt
coagulopathi
even
dic
sever
condit
seen
small
percentag
puuv
patient
lain
et
al
could
one
factor
contribut
hemorrhag
complic
seen
hfr
especi
sinc
increas
tf
express
proven
play
import
role
pathogenesi
viral
hemorrhag
fever
like
marburg
ebola
geisbert
et
al
b
sinc
alter
level
relat
renal
disturb
compar
seen
hantaviru
diseas
gong
et
al
malgorzewicz
et
al
function
polymorph
relat
sever
diseas
acut
puuv
patient
lain
et
al
also
studi
regul
activ
infect
puuv
increas
product
would
vivo
lead
decreas
fibrinolysi
integrin
receptor
play
import
role
complex
format
zhou
et
al
increas
express
puuv
infect
combin
competit
bind
hantaviru
vitronectin
could
hypothet
lead
alter
halflif
stabil
increas
level
complex
supernat
puuv
infect
cell
strengthen
hypothesi
consid
increas
vitronectin
could
result
renal
impair
even
caus
nephritislik
respons
pledg
evalu
interact
integrin
vitronectin
hantavirus
mg
primari
investig
studi
perform
experi
data
analys
jm
e
bm
supervis
experi
raw
data
analysi
hypothesi
format
fa
cw
contribut
design
optimis
mainten
primari
huvec
cultur
jr
viral
kinet
kb
cell
thrombin
gener
test
contribut
design
implement
test
studi
hh
av
made
substanti
contribut
assist
cultiv
low
passag
puuv
isol
mg
jm
fa
jr
cw
kb
hh
av
ao
eg
bm
contribut
plan
manuscript
data
analysi
interpret
critic
review
approv
manuscript
albert
e
osterhau
consult
viroclin
bioscienc
bv
spin
erasmu
mc
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
